Institution
University of Göttingen
Education•Göttingen, Germany•
About: University of Göttingen is a education organization based out in Göttingen, Germany. It is known for research contribution in the topics: Population & Gene. The organization has 43851 authors who have published 86318 publications receiving 3010295 citations. The organization is also known as: Georg-August-Universität Göttingen & Universität Göttingen.
Topics: Population, Gene, Species richness, Context (language use), Catalysis
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In a multinational, double-blind, placebo-controlled trial (NCT00474058), 287 subjects with Parkinson's disease (PD) and unsatisfactory early-morning motor symptom control were randomized 2:1 to receive rotigotine (2-16 mg/24 hr [n = 190] or placebo (n = 97) as discussed by the authors.
Abstract: In a multinational, double-blind, placebo-controlled trial (NCT00474058), 287 subjects with Parkinson's disease (PD) and unsatisfactory early-morning motor symptom control were randomized 2:1 to receive rotigotine (2–16 mg/24 hr [n = 190]) or placebo (n = 97). Treatment was titrated to optimal dose over 1–8 weeks with subsequent dose maintenance for 4 weeks. Early-morning motor function and nocturnal sleep disturbance were assessed as coprimary efficacy endpoints using the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (Motor Examination) measured in the early morning prior to any medication intake and the modified Parkinson's Disease Sleep Scale (PDSS-2) (mean change from baseline to end of maintenance [EOM], last observation carried forward). At EOM, mean UPDRS Part III score had decreased by −7.0 points with rotigotine (from a baseline of 29.6 [standard deviation (SD) 12.3] and by −3.9 points with placebo (baseline 32.0 [13.3]). Mean PDSS-2 total score had decreased by −5.9 points with rotigotine (from a baseline of 19.3 [SD 9.3]) and by −1.9 points with placebo (baseline 20.5 [10.4]). This represented a significantly greater improvement with rotigotine compared with placebo on both the UPDRS Part III (treatment difference: −3.55 [95% confidence interval (CI) −5.37, −1.73]; P = 0.0002) and PDSS-2 (treatment difference: −4.26 [95% CI −6.08, −2.45]; P < 0.0001). The most frequently reported adverse events were nausea (placebo, 9%; rotigotine, 21%), application site reactions (placebo, 4%; rotigotine, 15%), and dizziness (placebo, 6%; rotigotine 10%). Twenty-four-hour transdermal delivery of rotigotine to PD patients with early-morning motor dysfunction resulted in significant benefits in control of both motor function and nocturnal sleep disturbances. © 2010 Movement Disorder Society
376 citations
••
TL;DR: Data show that only one region in the ventromedial prefrontal cortex (VMPFC) controlled negative affective responses and reduced the degree of subjectively perceived unpleasantness independent of the experimental domain, which strongly imply that the human VMPFC may represent a domain-general controller of perceived fear and aversiveness that modulates negative affectives in phylogenetically older structures of the emotion processing system.
376 citations
••
TL;DR: In a first feasibility study employing a novel ELISA, this work found relatively low CSF alphaS concentrations in subjects with parkinsonism linked to synucleinopathy, PD and DLB, and recorded a marked rise in total CSFalphaS resulting from rapid cell death in definite prion disease cases.
376 citations
••
University of Gothenburg1, Tohoku University2, University of Rome Tor Vergata3, VU University Amsterdam4, Alzheimer's Association5, New York State Office for People With Developmental Disabilities6, Innogenetics7, University of Perugia8, Karolinska Institutet9, Washington University in St. Louis10, University of São Paulo11, University of California, San Diego12, University of Milan13, Goethe University Frankfurt14, Aarhus University15, University of Bonn16, Harvard University17, University of Eastern Finland18, Innsbruck Medical University19, University of Tübingen20, Heidelberg University21, National and Kapodistrian University of Athens22, Janssen Pharmaceutica23, University of Szeged24, Edith Cowan University25, University of Erlangen-Nuremberg26, University of Melbourne27, Johnson & Johnson28, Johns Hopkins University29, University of Washington30, University of Ulm31, Mayo Clinic32, Radboud University Nijmegen33, University of Pennsylvania34, University of Oslo35, University of Göttingen36
TL;DR: The cerebrospinal fluid biomarkers amyloid β (Aβ)‐42, total‐Tau (T‐tau), and phosphorylated‐t Tau (P‐tAU) demonstrate good diagnostic accuracy for Alzheimer's disease (AD), but there are large variations in biomarker measurements between studies, and between and within laboratories.
Abstract: Background
The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer’s disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer’s Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program.
375 citations
••
TL;DR: The basic function of spinal motor systems in motor control is to initiate and organize the course of movements, which involves transmission and coordination of descending information for the performance of centrally induced movements and their adaptation to peripheral conditions.
375 citations
Authors
Showing all 44172 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yang Gao | 168 | 2047 | 146301 |
J. S. Lange | 160 | 2083 | 145919 |
Jens J. Holst | 160 | 1536 | 107858 |
Hans Lassmann | 155 | 724 | 79933 |
Walter Paulus | 149 | 809 | 86252 |
Arnulf Quadt | 135 | 1409 | 123441 |
Elizaveta Shabalina | 133 | 1421 | 92273 |
Ernst Detlef Schulze | 133 | 670 | 69504 |
Mark Stitt | 132 | 456 | 60800 |
Meinrat O. Andreae | 131 | 700 | 72714 |
Teja Tscharntke | 130 | 520 | 70554 |
William C. Hahn | 130 | 448 | 72191 |
Vladimir Cindro | 129 | 1157 | 82000 |
Dave Britton | 129 | 1094 | 84187 |
Johannes Haller | 129 | 1178 | 84813 |